Todos os estudos
RecrutamentoFASE2, FASE3INTERVENCIONISTA

AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)

This research is looking into a new gene therapy, RGX-202, for Duchenne muscular dystrophy (DMD). DMD is a condition where muscles weaken over time because a vital protein called dystrophin is missing. RGX-202 is designed to help muscle cells make a working version of this protein. The study will test how safe the treatment is, how well people tolerate it, and if it helps improve muscle strength. It's a multi-stage study, starting with a smaller group to check safety, then expanding to more boys. Participants will receive a single treatment given through a drip, and their health will be monitored for about two years afterwards.

Em resumo

Status
Recrutamento
Fase
FASE2, FASE3
Patrocinador
REGENXBIO Inc.
Meta de inscrição
65
Iniciar
04 Jan 2023
Conclusão estimada
01 Aug 2028

Sobre o que é este estudo?

Duchenne muscular dystrophy (DMD) is a genetic condition that causes muscles to become weak and waste away over time. This happens because the body can't make enough of a key protein called dystrophin, which is essential for healthy muscle function. Without it, muscle cells get damaged, leading to ongoing problems.

This study is investigating a new treatment called RGX-202. It's a type of gene therapy, which means it works by introducing new genetic information into the body. Specifically, RGX-202 aims to deliver a piece of genetic code to muscle cells. This code acts like a 'recipe' for a special, smaller version of the dystrophin protein that can still help muscles work.

The main goals of this research are to find out if RGX-202 is safe, if boys with DMD can tolerate the treatment well, and if it helps improve their muscle strength and function. The treatment is given once, through a drip into the vein. Boys in the study will also receive other medicines for a short time to prevent their body from reacting negatively to the gene therapy.

Pontos principais

  • Tests a new gene therapy (RGX-202) for Duchenne muscular dystrophy.
  • Aims to help muscles make a working version of a missing protein.
  • Treatment is a single dose given into a vein.
  • Study monitors participants for around two years after treatment.
  • Participants will also take short-term medicines to help with the treatment.
  • Open to male participants aged 1 to <12 years old.

Quem pode ser elegível?

This study is looking for boys who have Duchenne muscular dystrophy. They need to be male and at least 1 year old, but less than 12 years old. They should also meet a certain weight requirement (at least 10 kg).

To be considered, participants generally need to have specific changes in their DMD gene and may need to be able to walk a certain distance independently. They should also have been on a stable dose of steroid medication (a common treatment for DMD) for at least 12 weeks. Your doctor will check your child's general health, including their liver and kidney function, to make sure they are healthy enough to take part.

It's important that the child's parent or legal guardian understands the study and agrees to participate, and that they can bring their child to all scheduled appointments and follow the study instructions.

Este estudo pode ser adequado para você?

Responda a estas perguntas rápidas para ver se você pode ser elegível. Este é apenas um guia — a decisão final é da equipe de pesquisa.

  1. Is my child male and between 1 and 12 years old?
  2. Does my child have a confirmed diagnosis of Duchenne muscular dystrophy?
  3. Can my child walk independently, or with minimal help (depending on the specific group)?
  4. Has my child been on a steady dose of steroid medication for at least 3 months?
  5. Are we able and willing to attend all study appointments over about two years?
Responda a todas as perguntas para ver o seu resultado.

O que envolve a participação?

If you join this study, your child will receive the RGX-202 treatment once, through a drip into their vein. Before and during the treatment, your child will also take other medicines for a short time to help prevent any strong reactions to the gene therapy.

The study involves regular visits to the clinic over roughly two years to check your child's health, how they are tolerating the treatment, and if their muscles are improving. These visits will include various assessments, such as physical examinations, blood tests, and tests to measure muscle strength and function. After the main study period, there might be an option to join a separate long-term follow-up study to continue monitoring your child's health.

Riscos e benefícios potenciais

Taking part in any clinical trial involves both potential benefits and risks. The potential benefit of this study is that RGX-202 could help improve muscle strength and overall health for boys with Duchenne muscular dystrophy. However, as this is a new treatment, there might be side effects or risks that are not yet fully known. The study team will carefully monitor your child for any problems, and you'll be given detailed information about known risks. Remember, participation is completely voluntary, and you have the right to withdraw your child from the study at any time, for any reason, without it affecting their future medical care.

Localizações (17)

  • Arkansas Children's Hospital
    Código postal verificado
    Little Rock, Estados Unidos· Recrutamento
  • Stanford School of Medicine /Division of Neuromuscular Medicine
    Código postal verificado
    Palo Alto, Estados Unidos· Recrutamento
  • Children's Hospital Colorado
    Código postal verificado
    Aurora, Estados Unidos· Recrutamento
  • Universidade da Flórida
    Código postal verificado
    Gainesville, Estados Unidos· Recrutamento
  • Pesquisa de Doenças Raras
    Código postal verificado
    Atlanta, Estados Unidos· Recrutamento
  • Ann & Robert H. Lurie Children's Hospital of Chicago
    Código postal verificado
    Chicago, Estados Unidos· Recrutamento
  • Universidade de Iowa
    Código postal verificado
    Iowa City, Estados Unidos· Recrutamento
  • University of Massachusetts Chan Medical School
    Código postal verificado
    Worcester, United States· Recrutamento
  • Cincinnati Children's
    Código postal verificado
    Cincinnati, Estados Unidos· Recrutamento
  • Oregon Health & Science University
    Código postal verificado
    Portland, Estados Unidos· Recrutamento
  • The University of Texas Southwestern Medical Center
    Código postal verificado
    Dallas, Estados Unidos· Recrutamento
  • Children's Hospital of the King's Daughters
    Código postal verificado
    Norfolk, United States· Recrutamento

Perguntas frequentes

O que é a distrofia muscular de Duchenne?

It's a genetic condition that causes muscles to become weak and waste away over time because the body can't make enough of a protein called dystrophin.

What is RGX-202?

It's a new gene therapy treatment designed to help muscle cells make a useful, smaller version of the missing dystrophin protein.

How is the treatment given?

It's given once as a single injection into a vein (like a drip).

How long will my child be in the study?

Participants will be monitored for about two years after receiving the treatment, with regular check-ups.

Can girls join the study?

No, this specific study is only for male participants.

Como saber mais

Patient Advocacy

Sempre consulte seu médico ou especialista antes de decidir participar de um estudo.

Interessado em participar?

Registre seu interesse

Compartilhe seus detalhes e a equipe de pesquisa para "AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With…" entrará em contato com você se você for elegível. Sempre fale com seu médico antes de concordar em participar.

Discussão

Discussão da comunidade

Desenvolvido pelo nosso fórum em community.patient.info. Por favor, seja respeitoso — isto não é um conselho médico.